Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.42.

HCAT has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Tuesday, August 20th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of Health Catalyst in a research report on Tuesday, May 21st. JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Stephens decreased their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Finally, Piper Sandler dropped their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the transaction, the chief operating officer now directly owns 155,215 shares in the company, valued at approximately $954,572.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total transaction of $32,029.20. Following the completion of the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The disclosure for this sale can be found here. Insiders sold 34,037 shares of company stock worth $236,872 in the last 90 days. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HCAT. Nisa Investment Advisors LLC lifted its stake in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Quarry LP raised its holdings in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares in the last quarter. Perfromance Wealth Partners LLC purchased a new stake in shares of Health Catalyst during the second quarter valued at about $64,000. Mackenzie Financial Corp purchased a new stake in shares of Health Catalyst during the second quarter valued at about $70,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Health Catalyst in the 4th quarter valued at about $108,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT opened at $8.44 on Wednesday. The company has a market capitalization of $498.26 million, a P/E ratio of -4.56 and a beta of 1.31. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The firm’s 50 day simple moving average is $7.05 and its two-hundred day simple moving average is $6.89.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter in the previous year, the company earned ($0.21) EPS. Health Catalyst’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, sell-side analysts anticipate that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.